HOME
NATION
NATION (OPINION)
BUSINESS & ECONOMY
INTERNATIONAL
SCIENCE & TECHNOLOGY
ENTERTAINMENT
LIFESTYLE & FASHION
SPORTS
TRAVEL
NATION
NATION (OPINION)
BUSINESS & ECONOMYINTERNATIONAL
SCIENCE & TECHNOLOGY
ENTERTAINMENT
LIFESTYLE & FASHION
SPORTS
TRAVEL
MORE STORIES President assures Leh of help, praises army Government may press panic button on Kashmir: BJP Digvijay objects to Chidambaram's saffron terror remarks Rubabuddin charges Modi with contempt of apex court Have to consider options to save question hour: Ansari US Open: Sania Mirza's run ends in women's singles Third generation mobile services to hit the markets soon Secrets of Asia's first global city Pakistani Taliban added to US terror list US hostage crisis ends as gunman shot dead
© 2008-2010 Dmanewsdesk.com
- All Rights Reserved.
- All Rights Reserved.
New AIDS vaccine ready for trials
July 1, 2009
Toronto: The Canadian University of Western Ontario has developed a new HIV/AIDS vaccine that is ready for human trials.
The vaccine called SAV001H has been developed by the university at London, about 160 km from here, in collaboration with Sumagen Canada, a subsidiary of the Korean pharmaceutical company.
In a statement Tuesday, Sumagen Canada said it has submitted an application to the US Food and Drug Administration (FDA) to begin the first phase of trials of the vaccine on human beings.
Chil-Yong Kang, a professor at the university, said they have completed safety and immunogenicity studies of the vaccine on animals. Immunogenicity measures the ability of a drug or vaccine to provoke an immune response in the body.
Trials of the new vaccine on animals have reportedly resulted in good anti-body reactions with no adverse effects.
Numerous trials have been carried out by pharmaceutical companies to develop vaccines since the AIDS virus was recognized in 1983, but no commercialised vaccine has been developed so far.
Sumagen Canada has secured patents for the vaccine in over 70 countries, including the US, the European Union and Korea.
It said the phase one clinical trials of the vaccine will double check its safety on HIV positive volunteers. The phase two trials would assess the immunogenicity of the vaccine.
Sumagen Canada said it is ready for clinical trials in the US as soon the FDA approval is granted.
The University of Western Ontario and the city of London have been short-listed by the Canadian government to set up an $88 million HIV vaccine manufacturing facility, which will be partly funded by the Bill and Melinda Gates Foundation.
Just last week Canadian scientists had announced a major breakthrough in AIDS treatment by saying that they have found where the HIV virus hides in the human body.
Currently, AIDS patients have to take a cocktail of up to five to six drugs to prolong their life up to 13 years.
There are over 33 million HIV patients worldwide, with 2.7 million more getting infected each year.
The vaccine called SAV001H has been developed by the university at London, about 160 km from here, in collaboration with Sumagen Canada, a subsidiary of the Korean pharmaceutical company.
In a statement Tuesday, Sumagen Canada said it has submitted an application to the US Food and Drug Administration (FDA) to begin the first phase of trials of the vaccine on human beings.
Chil-Yong Kang, a professor at the university, said they have completed safety and immunogenicity studies of the vaccine on animals. Immunogenicity measures the ability of a drug or vaccine to provoke an immune response in the body.
Trials of the new vaccine on animals have reportedly resulted in good anti-body reactions with no adverse effects.
Numerous trials have been carried out by pharmaceutical companies to develop vaccines since the AIDS virus was recognized in 1983, but no commercialised vaccine has been developed so far.
Sumagen Canada has secured patents for the vaccine in over 70 countries, including the US, the European Union and Korea.
It said the phase one clinical trials of the vaccine will double check its safety on HIV positive volunteers. The phase two trials would assess the immunogenicity of the vaccine.
Sumagen Canada said it is ready for clinical trials in the US as soon the FDA approval is granted.
The University of Western Ontario and the city of London have been short-listed by the Canadian government to set up an $88 million HIV vaccine manufacturing facility, which will be partly funded by the Bill and Melinda Gates Foundation.
Just last week Canadian scientists had announced a major breakthrough in AIDS treatment by saying that they have found where the HIV virus hides in the human body.
Currently, AIDS patients have to take a cocktail of up to five to six drugs to prolong their life up to 13 years.
There are over 33 million HIV patients worldwide, with 2.7 million more getting infected each year.
Business & Economy
Experts question the method to calculate GDP
Telcos set to roll out 3G services; welcome spectrum allocation
Third generation mobile services to hit the markets soon
LTA to enjoy tax exemption in new regime
Gold sets new record at Rs 19,405
World Bank cites Andhra water project for food security
Pak match-fixing scandal: Butt, Asif, Amir to face Pak Cricket Board today
I-T finds Lalit Modi link to 80cr private jet deal
Indian economy grows by 8.8 per cent in April-June
BlackBerry gives in, India grants two month extension
Swiss banks will share account info of tax evaders
Tata Steel conferred ‘Rashtriya Khel Protsahan Puruskar’
Significant decline in inflation by year end: Ahluwalia
Pakistan-England match-fixing scandal: Butt is ringleader, alleges bookie
Pakistan-England match-fixing scandal: Butt is ringleader, alleges bookie
A PIL that unravelled one of India's biggest scams
Ford recalls over 460,000 mini vans
Sheila Dikshit now sets Sept 15 as deadline for CWG venues
SC refuses to stay Sesa Goa open offer for Cairn
BlackBerry says no 'master key' to access encrypted data
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
